Coeliac disease

Intestinal tract
#Coeliac disease #Monoclonal antibodies #Phase II trial #Teva

Positive results for anti-IL-15 monoclonal antibody in coeliac disease

Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease.   The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week… Read More

#News